Table 4.
Changes from baseline in clinical and health-related quality of life outcomes
| Clinical measure | Treatment group | Baseline mean (SD) | 6-month mean (SD) | Percentage change | p value |
|---|---|---|---|---|---|
| IPSS | PVP | 21.4 (6.4) | 8.2 (6.1) | −62% | 0.718 |
| TURP | 24.4 (4.4) | 10.5 (8.3) | −57% | ||
|
| |||||
| Urinary frequency (IPSS 2 hours) | PVP | 3.7 (1.2) | 1.7 (1.4) | −53% | 0.544 |
| TURP | 3.7 (1.2) | 2.0 (1.5) | −46% | ||
|
| |||||
| Max flow rate (Qmax) | PVP | 11.1 (4.2) | 17.2 (10.1) | +55% | 0.705 |
| TURP | 8.8 (4.1) | 15.8 (8.7) | +79% | ||
|
| |||||
| Postvoid residual volume (mL) | PVP | 106.9 (108.5) | 30.58 (50.2) | −71% | 0.018 |
| TURP | 68.8 (69.1) | 43.4 (69.1) | −31% | ||
|
| |||||
| Erectile function (SHIM score) | PVP | 12.4 (7.8) | 11.4 (8.7) | −7% | 0.569 |
| TURP | 9.4 (8.8) | 9.3 (9.3) | −2% | ||
|
| |||||
| PSA | PVP | 2.9 (2.5) | 2.8 (2.9) | −2% | 0.050 |
| TURP | 3.0 (2.1) | 2.2 (1.7) | −29% | ||
|
| |||||
| PSA without pre 5-ARI use | PVP | 3.2(2.1) | 2.6 (3.8) | −19% | 0.581 |
| TURP | 2.7 (2.0) | 1.9 (2.0) | −28% | ||
|
| |||||
| EQ-5D | PVP | 0.87 (0.1) | 0.91 (0.1) | +5% | 0.134 |
| TURP | 0.89 (0.1) | 0.88 (0.1) | −1% | ||
TURP: transurethral resection of the prostate; PVP: photoselective vaporization of the prostate; SD: standard deviation; IPSS: international prostate symptoms score; SHIM: sexual health inventory for men; PSA: prostate-specific antigen; EQ-5D: EuroQol quality of life questionnaire.